Intranasal Vaccine Using Probiotic E. coli Vesicles Shows Potential in Inducing Mucosal Immunity Against Pneumococcal Infections

A recent study has demonstrated that intranasal vaccination using probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides can elicit mucosal immunity. Researchers investigated the potential of this novel vaccine approach to stimulate immune responses against Streptococcus pneumoniae, a pathogen responsible for various respiratory infections.

The study focused on utilizing outer membrane vesicles (OMVs) derived from genetically engineered probiotic E. coli strains. These OMVs were modified to display pneumococcal capsular polysaccharides, which are key components of the bacterial surface and play a role in immune recognition. The researchers administered the vaccine intranasally to test its ability to induce localized mucosal immunity, an important defense mechanism against respiratory pathogens. Results showed that the vaccination successfully triggered immune responses in mucosal tissues, suggesting its potential as an effective strategy for combating pneumococcal infections. Further research is needed to evaluate its efficacy and safety in broader applications.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 23, 2025

Author

GOAI